📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-29 18:58
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
13 announcements match the current filters (relevance ≥ 5).
Pfizer Approves Rs 75 Per Share Final Dividend at 75th AGM
Pfizer Limited's shareholders have officially approved all resolutions at the 75th Annual General Meeting held on July 28, 2026. The key highlight is the declaration of a final dividend of Rs 75 per equity share (750% of face value) for the financial year ended March 31, 2026. The voting results showed overwhelming support, with the dividend resolution receiving 99.9998% votes in favor. Additionally, shareholders ratified the appointment of Mr. P. Rengan as Director and the remuneration for cost auditors for FY 2026-27.
Confidence: HIGH
What changedShareholders have formally ratified the financial results for FY 2025-26 and the dividend payout proposed by the board.
Why it mattersThe approval confirms a significant cash return to shareholders and ensures corporate governance continuity through the re-appointment of directors and auditors.
Final Dividend: Rs 75 per shareDividend Percentage: 750%Record Date: July 17, 2026Total Shareholders: 1,05,890Votes in Favor (Dividend): 99.9998%
📅 Short termThe stock may see neutral to slightly positive sentiment as the dividend is now officially confirmed for payout.
📈 Long termLimited; this is a routine annual procedure confirming the company's established dividend-paying track record.
Key Highlights
Final dividend of Rs 75 per equity share (750%) approved for FY 2025-26
Total of 1,05,890 shareholders were on record as of the July 17, 2026 record date
AGM voting turnout represented 81.96% of total shares, with 3,74,95,845 votes polled
Resolution for dividend declaration passed with 99.9998% of votes in favor
Promoter group holding of 63.92% (2,92,43,042 shares) voted entirely in favor of all resolutions
👀 What to Watch
Investors should note the official approval of the Rs 75 dividend and monitor the company's announcement regarding the specific payment date.
₹75 Dividend Approved at Pfizer Limited's 75th Annual General Meeting
Pfizer Limited concluded its 75th AGM on July 28, 2026, where shareholders approved a dividend of ₹75 per equity share (750%). The meeting included the adoption of audited financial statements for the year ended March 31, 2026, and the re-appointment of Mr. P. Rengan as Director. Managing Director Meenakshi Nevatia provided an overview of the company's performance, focusing on new product introductions and the specialty science portfolio. The company also ratified the remuneration for cost auditors for the 2026-27 financial year.
Confidence: HIGH
What changedShareholders formally approved the FY26 financial results and a significant dividend payout of ₹75 per share.
Why it mattersIt reinforces the company's cash-return profile and provides a platform for management to update on the transition toward a patented global product portfolio.
Dividend per share: ₹75Dividend percentage: 750%Net Worth: ₹4203 CrDebt: ₹70 CrROCE: 24.0%
📅 Short termThe stock may see neutral to positive sentiment as the ₹75 dividend is formalized, though the impact is likely already partially priced in.
📈 Long termStructural focus on high-margin patented products and specialty therapies remains the key value driver for this MNC pharma player.
⚠ Risk flags
- Dependency on hospital footfalls
- Pediatric clinic closure risks
- Low expected growth rate of 0.8-2%
Key Highlights
Approved a dividend of ₹75 per equity share (750%) for the financial year ended March 31, 2026
The 75th AGM was conducted virtually and concluded within 2 hours and 17 minutes
Management highlighted the strategy of increasing the share of global patented products, which reached 48.6% of sales
Ratified remuneration for Cost Auditors for the financial year ending March 31, 2027
👀 What to Watch
Monitor the dividend credit timeline and track the execution of the 'three-pronged strategy' involving specialty science and hybrid go-to-market models in upcoming quarterly results.
₹204.47 Cr Q1 Net Profit: Pfizer Reports 6.6% YoY Growth in Bottom Line
Pfizer Limited reported a steady performance for the quarter ended June 30, 2026, with revenue from operations rising 8.3% YoY to ₹653.17 crore. Net profit increased by 6.6% to ₹204.47 crore, up from ₹191.75 crore in the corresponding quarter of the previous year. The company maintained strong profitability with a PAT margin of approximately 31.3%. Notably, there were no exceptional items this quarter, unlike the previous financial year which saw significant separation costs related to brand distribution shifts.
Confidence: HIGH
What changedThe company has transitioned into the new fiscal year with steady single-digit growth in revenue and profit, moving past the exceptional separation costs incurred in FY2025-26.
Why it mattersThe results confirm Pfizer's ability to maintain high margins (31%+) and steady growth in the Indian market, supported by its shift toward a specialty and patented product portfolio.
Revenue from Operations: ₹653.17 crNet Profit: ₹204.47 crYoY Revenue Growth: 8.3%PAT Margin: 31.3%EPS: ₹44.69
📅 Short termThe stock is likely to remain stable or see mild positive interest as the results meet expectations for steady growth in the MNC pharma space.
📈 Long termPfizer's long-term value depends on its ability to introduce global patented drugs to India and leverage its hybrid sales model to expand market share in chronic and specialty therapies.
⚠ Risk flags
- Concentration risk in specialty therapies
- Regulatory pricing pressures on legacy brands
- Dependency on parent company's global product pipeline
Key Highlights
Revenue from operations increased to ₹653.17 crore from ₹603.05 crore in the year-ago quarter.
Net profit for the period stood at ₹204.47 crore, representing a 6.6% YoY growth.
Earnings Per Share (EPS) improved to ₹44.69 from ₹41.91 in June 2025.
Total expenses were well-managed at ₹421.33 crore, despite a ₹182.89 crore spend on stock-in-trade purchases.
Other income saw a decline to ₹44.84 crore compared to ₹67.17 crore in the same period last year.
👀 What to Watch
Investors should monitor the volume growth in legacy brands following the distribution agreement with Cipla and watch for the launch of new patented products from Pfizer's global portfolio.
CFO Amit Agarwal Resigns; Effective October 8, 2026
Pfizer Limited has announced the resignation of Mr. Amit Agarwal from his positions as Executive Director – Finance and Chief Financial Officer (CFO). The resignation is effective from the close of business on October 8, 2026, as he intends to pursue a professional opportunity outside the company. Mr. Agarwal will also vacate his seat on the Board of Directors and three key committees, including Risk Management and CSR. The company has approximately two and a half months to manage the transition for this Key Managerial Personnel (KMP) role.
Confidence: HIGH
What changedMr. Amit Agarwal is stepping down as the CFO and Executive Director of Pfizer Limited to join another organization.
Why it mattersThe CFO is a critical Key Managerial Personnel responsible for financial reporting and risk management; while routine in large MNCs, leadership stability is important for maintaining investor confidence.
Effective Date of Resignation: October 8, 2026Net Worth: Rs 4203 CrDebt: Rs 70 CrDec 2025 Quarterly Revenue: Rs 645.03 CrPromoter Holding: 63.92%
📅 Short termThe market is likely to react neutrally as the resignation is not immediate, allowing time for a successor search.
📈 Long termLimited structural impact expected given Pfizer's established global systems and processes, provided a competent successor is appointed.
⚠ Risk flags
- Potential for temporary leadership transition risk if a successor is not named before the October deadline
Key Highlights
Resignation of CFO and Executive Director effective October 8, 2026
Transition period of 73 days provided from the announcement date of July 27, 2026
Cessation of membership in 3 board committees: CSR, Risk Management, and Board Administrative & Share Transfer
Company reports a strong financial position with a Net Worth of Rs 4,203 Cr and low Debt of Rs 70 Cr
👀 What to Watch
Watch for the announcement of a successor to the CFO role to ensure continuity in financial oversight and strategic execution.
Pfizer announces Rs 75 per share final dividend; Record date set for July 17, 2026
Pfizer Limited has announced a final dividend of Rs 75 per equity share for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine shareholder eligibility for this payout. The 75th Annual General Meeting (AGM) is scheduled for July 28, 2026, via video conferencing. Dividend payments are expected to commence on or after August 4, 2026, subject to shareholder approval at the AGM.
Confidence: HIGH
What changedThe company has formalized the timeline for its annual dividend payout and the 75th Annual General Meeting.
Why it mattersThe Rs 75 per share dividend represents a significant cash return to shareholders, reflecting a dividend yield of approximately 1.66% based on the current price of Rs 4527.
Final Dividend: Rs 75 per shareDividend Yield (approx): 1.66%Record Date: July 17, 2026AGM Date: July 28, 2026Payment Date: August 4, 2026
📅 Short termThe stock may witness interest leading up to the record date of July 17 as investors seek to qualify for the Rs 75 dividend.
📈 Long termLimited; this is a routine annual distribution of profits consistent with the company's historical payout practices.
Key Highlights
Final dividend declared at Rs 75 per equity share for FY 2025-26
Record date for dividend eligibility is July 17, 2026
75th Annual General Meeting scheduled for July 28, 2026, at 3:00 PM IST
Dividend payment to be processed on or after August 4, 2026
Remote e-voting period runs from July 24 to July 27, 2026
👀 What to Watch
Shareholders should ensure their bank account and KYC details are updated with their Depository Participant or RTA by the July 17 record date to ensure seamless dividend credit.
₹75 Final Dividend Recommended; 75th AGM Scheduled for July 28, 2026
Pfizer Limited has issued a notice for its 75th Annual General Meeting (AGM) to be held on July 28, 2026. The Board has recommended a final dividend of ₹75 per equity share (750%) for FY 2025-26, with a record date of July 17, 2026. Key agenda items include the adoption of audited financial statements and the re-appointment of Mr. P. Rengan as Director. The company also disclosed transferring ₹1.65 crore in unclaimed dividends to the IEPF during the last financial year.
Confidence: HIGH
What changedThe company has formalized the timeline for its 75th AGM and the payout of its previously recommended ₹75 per share dividend.
Why it mattersThe dividend represents a significant cash return to shareholders, yielding approximately 1.6% at current market prices, reflecting the company's strong cash position and low debt (₹70 Cr).
Final Dividend: ₹75 per shareDividend Percentage: 750%Record Date: July 17, 2026Unclaimed Dividend Transferred: ₹1.65 crIEPF Share Balance: 4,34,170 units
📅 Short termThe stock is likely to remain supported in the near term as it approaches the dividend record date of July 17.
📈 Long termStructural growth depends on the company's ability to launch new patented products from its global basket, as legacy brands face generic competition.
⚠ Risk flags
- Dependency on hospital footfalls and pediatric clinic operations for revenue growth.
Key Highlights
Final dividend of ₹75 per equity share (750% of face value) recommended for FY 2025-26.
Record date for dividend eligibility is July 17, 2026, with payment starting August 4, 2026.
Total shares held in the IEPF account stood at 4,34,170 as of March 31, 2026.
Unclaimed dividend amounting to ₹1.65 crore was transferred to the IEPF during the financial year.
Remote e-voting period is scheduled from July 24, 2026, to July 27, 2026.
👀 What to Watch
Investors should ensure their bank details are updated by the record date of July 17, 2026, to receive the ₹75/share dividend. Watch for the full Annual Report for updates on the global patented product pipeline.
Pfizer Ltd Announces Final Dividend of Rs 75 per Share; Sets Record Date for July 17, 2026
Pfizer Limited has recommended a substantial final dividend of Rs. 75 per equity share for the financial year ended March 31, 2026. This represents a 750% payout on the face value of Rs. 10 per share. The company has officially fixed July 17, 2026, as the record date to determine the eligibility of shareholders for this payout. This announcement follows the board meeting held on May 12, 2026, reflecting a strong commitment to shareholder returns.
Key Highlights
Recommended final dividend of Rs. 75 per equity share for FY 2025-26
Dividend payout represents 750% of the face value of Rs. 10 per share
Record date for determining dividend entitlement is fixed as July 17, 2026
The recommendation was finalized during the Board of Directors meeting on May 12, 2026
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date, which is typically one business day prior to the July 17 record date. The high absolute dividend amount makes it an attractive proposition for yield-seeking investors.
Pfizer Ltd Announces Rs 75 per Share Dividend; Reports Audited FY26 Results
Pfizer Limited has recommended a substantial final dividend of Rs. 75 per equity share (750% of face value) for the financial year ended March 31, 2026. The company reported its audited financial results for FY26, maintaining a debt-free status with no outstanding long-term borrowings exceeding Rs. 1,000 crores. The dividend is subject to shareholder approval at the upcoming 75th AGM on July 28, 2026, with a record date set for July 17, 2026. This announcement reflects the company's strong cash position and commitment to shareholder returns.
Key Highlights
Recommended a final dividend of Rs. 75 per equity share of Rs. 10 each (750%) for FY 2025-26.
Record date for dividend eligibility is fixed as Friday, July 17, 2026.
Dividend payment to be processed on or after August 4, 2026, post-AGM approval.
Confirmed non-applicability of 'Large Corporate' status with zero debt securities issued.
Appointed M/s. Kishore Bhatia & Associates as Cost Auditors for the financial year 2026-27.
👀 What to Watch
Investors should note the record date of July 17, 2026, to qualify for the high dividend payout. The company's debt-free balance sheet and consistent dividend policy remain key positives for long-term portfolios.
Pfizer Ltd Recommends ₹75 Per Share Final Dividend for FY26
Pfizer Limited's Board has recommended a substantial final dividend of ₹75 per equity share (750% of face value) for the financial year ended March 31, 2026. The company has fixed July 17, 2026, as the record date to determine shareholder eligibility for this payout. Additionally, the company reported its audited financial results for FY26 and confirmed it remains debt-free with no long-term borrowings exceeding ₹1,000 crores. The 75th Annual General Meeting is scheduled for July 28, 2026, to seek shareholder approval for these items.
Key Highlights
Recommended a final dividend of ₹75 per equity share of ₹10 each for FY 2025-26.
Record date for dividend eligibility is Friday, July 17, 2026, with payment starting August 4, 2026.
Company confirmed it does not fall under the 'Large Corporate' category with zero debt securities issued.
Appointed M/s. Kishore Bhatia & Associates as Cost Auditors for the financial year 2026-27.
75th Annual General Meeting to be held on July 28, 2026, via Video-Conferencing.
👀 What to Watch
Investors should maintain their positions to benefit from the high dividend payout, ensuring they hold shares before the July 17 record date. The company's debt-free status and consistent dividend policy reflect a strong and stable financial position.
Pfizer Limited Receives ₹85.74 Crore Income Tax Demand for FY 2022-23
Pfizer Limited has received an assessment order from the Income-tax Department for the financial year 2022-23, involving a tax demand of ₹85.74 crore. The demand stems from alleged under-reporting of income due to the disallowance of certain expenses in the company's tax returns. Additionally, the department has issued a show cause notice to initiate penalty proceedings. The company intends to contest the order through an appeal and believes it has strong legal grounds to defend its position.
Key Highlights
Total tax demand amounting to ₹85,73,96,440 (₹85.74 crore) for FY 2022-23
Order issued under section 143(3) read with sections 144C(3) & 144B of the Income Tax Act
Show cause notice issued for penalty proceedings under section 274 read with section 270A
Company is evaluating the order and plans to file an appeal or application for stay
Management expects no immediate material impact on financial position or operations
👀 What to Watch
Investors should monitor the outcome of the company's appeal, as a final adverse ruling could impact cash flows, though the company currently maintains a strong legal stance.
Pfizer Ltd Q3 Net Profit Rises 11% YoY to ‡141.8 Cr; Revenue Up 20%
Pfizer Limited reported a strong 20% year-on-year growth in revenue from operations, reaching ‡645.03 crore for the quarter ended December 31, 2025. Despite an exceptional charge of ‡58.20 crore related to workforce restructuring and new labor code provisions, net profit grew by 11% to ‡141.84 crore. The company entered a strategic agreement with Cipla for the distribution of four key brands, leading to a one-time separation cost of ‡39.58 crore. Overall, the operational performance remains robust with a significant 19.7% improvement in nine-month profitability compared to the previous year.
Key Highlights
Revenue from operations grew 19.9% YoY to ‡645.03 crore from ‡537.99 crore in the previous year.
Net profit increased 11.2% YoY to ‡141.84 crore, overcoming a ‡58.20 crore exceptional charge.
Exceptional items include ‡39.58 crore for personnel separation following a distribution deal with Cipla for four brands.
A provision of ‡18.62 crore was recorded to account for the impact of the Government's New Labour Codes.
Nine-month net profit stands at ‡522.61 crore, up significantly from ‡436.66 crore in the corresponding period last year.
👀 What to Watch
Investors should focus on the strong double-digit revenue growth and the strategic partnership with Cipla which aims to optimize distribution for key brands. The one-time exceptional costs are non-recurring, indicating healthy underlying operational margins.
Pfizer Limited Signs 5-Year Exclusive Marketing Agreement with Cipla for Key Brands
Pfizer Limited has entered into a strategic 5-year exclusive agreement with Cipla Limited for the marketing and distribution of four major brands: Corex Dx, Corex LS, Dolonex, and Neksium in India. Under this partnership, Pfizer will continue to manufacture and supply these medicines while leveraging Cipla's extensive distribution network to enhance market reach. The transition will lead to a reduction in Pfizer's own field force, the financial impact of which will be disclosed in upcoming results. This move represents a significant shift in Pfizer's domestic commercial strategy to optimize operational efficiency.
Key Highlights
Exclusive 5-year agreement with Cipla for marketing and distribution of Corex Dx, Corex LS, Dolonex, and Neksium.
Pfizer retains all manufacturing, sourcing, and supply responsibilities for the specified brands.
The arrangement involves no upfront consideration, with commercial terms agreed upon for ongoing supply.
Move will result in a reduction of Pfizer's field force, with restructuring costs to be reported in ensuing results.
Partnership aims to leverage Cipla's 3rd rank position in the Indian pharma market for better brand penetration.
👀 What to Watch
Investors should monitor the upcoming quarterly results for one-time restructuring costs related to the field force reduction and evaluate if this outsourcing model improves Pfizer's operating margins over the long term.
Pfizer Partners with Cipla for Exclusive Marketing of 4 Key Brands for 5 Years
Pfizer Limited has entered into a strategic 5-year exclusive agreement with Cipla Limited for the marketing and distribution of four key brands: Corex Dx, Corex LS, Dolonex, and Neksium in India. Under this arrangement, Pfizer will continue to manufacture and supply these medicines while leveraging Cipla's extensive distribution network to enhance market reach. Notably, the company announced this shift will result in a reduction of its own field force, with the associated financial impact to be disclosed in upcoming quarterly results. This move indicates a strategic pivot towards a leaner operating model for these specific legacy brands.
Key Highlights
Exclusive 5-year marketing and distribution agreement signed with Cipla Limited for four major brands.
Brands included in the deal are Corex Dx, Corex LS, Dolonex, and Neksium.
Pfizer Limited will retain all manufacturing and supply responsibilities for the products.
The agreement will lead to a reduction in Pfizer's field force, with severance or transition costs to be reported later.
No upfront consideration was exchanged; commercial terms are based on ongoing supply and marketing arrangements.
👀 What to Watch
Investors should monitor the next financial statement for one-time restructuring costs related to the field force reduction. Long-term value depends on whether Cipla's distribution scale can drive enough volume growth to offset the change in margin structure.
